5yc0
From Proteopedia
(Difference between revisions)
| Line 6: | Line 6: | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yc0 OCA], [http://pdbe.org/5yc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yc0 RCSB], [http://www.ebi.ac.uk/pdbsum/5yc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yc0 ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5yc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5yc0 OCA], [http://pdbe.org/5yc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5yc0 RCSB], [http://www.ebi.ac.uk/pdbsum/5yc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5yc0 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Enfuvirtide (T20) is the only viral fusion inhibitor approved for clinical use, but it has relatively weak anti-HIV activity and easily induces drug resistance. In succession to T20, T1249 has been designed as a 39-mer peptide composed of amino acid sequences derived from HIV-1, HIV-2, and simian immunodeficiency virus (SIV); however, its development has been suspended due to formulation difficulties. We recently developed a T20-based lipopeptide (LP-40) showing greatly improved pharmaceutical properties. Here, we generated a T1249-based lipopeptide, termed LP-46, by replacing its C-terminal tryptophan-rich sequence with fatty acid. As compared to T20, T1249, and LP-40, the truncated LP-46 (31-mer) had dramatically increased activities in inhibiting a large panel of HIV-1 subtypes, with IC50 values approaching low picomolar (pM) concentrations. Also, LP-46 was an exceptionally potent inhibitor against HIV-2, SIV, and T20-resistant variants, and it displayed obvious synergistic effects with LP-40. Furthermore, we showed that LP-46 had increased helical stability and binding affinity with the target site. The crystal structure of LP-46 in complex with a target surrogate revealed its critical binding motifs underlying the mechanism of action. Interestingly, it was found that the introduced pocket-binding domain (PBD) in LP-46 did not interact with the gp41 pocket as expected; instead, it adopted a mode similar to that of LP-40. Therefore, our studies have provided an exceptionally potent and broad fusion inhibitor for developing new anti-HIV drugs, which can also serve as a tool to exploit the mechanisms of viral fusion and inhibition. | ||
| + | |||
| + | Exceptional Potency and Structural Basis of a T1249-Derived Lipopeptide Fusion Inhibitor against HIV-1, HIV-2, and Simian Immunodeficiency Virus.,Zhu Y, Zhang X, Ding X, Chong H, Cui S, He J, Wang X, He Y J Biol Chem. 2018 Feb 7. pii: RA118.001729. doi: 10.1074/jbc.RA118.001729. PMID:29425101<ref>PMID:29425101</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 5yc0" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Revision as of 07:13, 28 February 2018
Crystal structure of LP-46/N44
| |||||||||||
